1. A Hepatocellular Carcinoma Patient with TSC1 Mutations Benefits from Treatment with Everolimus: A Case Report
- Author
-
Man-Jiang Li, Shuo Wang, Hua-Sheng Shi, and Li-Qun Wu
- Subjects
Oncology ,medicine.medical_specialty ,Everolimus ,business.industry ,medicine.medical_treatment ,Gastroenterology ,TSC1 Gene Mutation ,Gene mutation ,Malignancy ,medicine.disease ,digestive system diseases ,Targeted therapy ,medicine.anatomical_structure ,Internal medicine ,Hepatocellular carcinoma ,medicine ,Surgery ,TSC1 ,business ,PI3K/AKT/mTOR pathway ,medicine.drug - Abstract
Hepatocellular carcinoma (HCC) has a high degree of malignancy and poor prognosis. Treatment options for patients with advanced HCC are limited. There is currently no evidence to approve the accumulation of targeted therapies for HCC to support the inhibition of the PI3K/Akt/mTOR signaling pathway as an effective therapeutic strategy. We report on a patient with advanced HCC carrying the TSC1 gene mutation who responded well to the mammalian target of rapamycin inhibitor everolimus. Computed tomography revealed tumor shrinkage and maintenance of partial remission after everolimus treatment for >12.3 months. To the best of our knowledge, this is the first clinical case report showing benefit from everolimus treatment in HCC patients with TSC1 gene mutations. Therefore, everolimus may be used as a potential targeted therapy for HCC with TSC1 gene mutation.
- Published
- 2020